Sanofi pulls leukaemia drug ahead of possible OK for Lemtrada

PARIS Mon Aug 20, 2012 10:19pm IST

Related Topics

Stocks

   

PARIS (Reuters) - Sanofi's rare disease unit Genzyme is pulling leukaemia drug Campath to prepare for its launch under a different dosage and as a multiple sclerosis treatment that will be branded as Lemtrada.

The withdrawal, meant to prevent the off-label use of Campath as a multiple sclerosis drug, is already under way in some European countries and will be effective in the United States on September 4, a Genzyme spokesman said.

Lemtrada, which Sanofi submitted for approval with health regulators in Europe and the United States in June, could be launched in 2013 if it wins approval.

If approved, it will be given far less frequently and in lower doses than Campath, and is one of the new products the French drugmaker is betting on to restore growth after losing several aging blockbusters to generic rivals.

"We think that this stoppage shows Sanofi's confidence in the approval of Lemtrada in multiple sclerosis," said Bryan Garnier analyst Eric Le Berrigaud, who estimates the drug could generate sales of $400 million in 2018, if approved.

The withdrawal will also enable Sanofi to adjust Lemtrada's price closer to that of rival multiple sclerosis drugs, Le Berrigaud said. Rivals include Tysabri, an injectable drug sold by Biogen Idec and Elan, while Novartis markets MS pill Gilenya.

Campath, which last year had sales of $76 million, will continue to be available through patient access programs in the 50 countries where it has been available since its launch in 2001.

"In most countries we will provide the drug for free, where this is permitted," the Genzyme spokesman said.

The news was first reported by trade publication BioCentury.

Sanofi shares, which have risen around 18 percent since the start of the year, closed 0.8 percent higher at 67.1 euros, outperforming France's main CAC-40 index, which closed 0.2 percent lower.

(Reporting by Elena Berton; Editing by David Cowell)

FILED UNDER:

REUTERS EXCLUSIVE

Reuters Showcase

Documentary Banned

Documentary Banned

Documentary on 2012 Delhi gang rape banned in India.  Full Article 

RBI Rate Cut

RBI Rate Cut

RBI surprises with post-budget rate cut.  Full Article 

Bollywood Focus

Bollywood Focus

Franchise Man swoops in to save Bollywood.  Full Article 

Snowden seeks Return

Snowden seeks Return

Fugitive ex-NSA contractor Snowden seeks to come home - lawyer.  Full Article 

Carry Your Litter

Carry Your Litter

Nepal tells Mount Everest litterbugs to take out the trash.  Full Article 

Healthcare Mess

Healthcare Mess

Exclusive - Payment delays dent India's flagship health, AIDS programmes  Full Article 

Reuters Interview

Reuters Interview

Budget lacks wow, but good enough: Jim O’Neill.  Full Article 

Defence Budget

Defence Budget

China defence budget rise to defy slowing economy.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage